A retrospective study evaluating universal direct antiglobulin test screening among 4,340 newborns at a tertiary care center in Riyadh, Saudi Arabia, revealed that ABO incompatibility accounted for the vast majority of positive cases and was generally accompanied by mild clinical courses. Out of the total cohort delivered and tested at King Fahad Medical City, 267 infants, or 6.1 percent, yielded a positive direct antiglobulin test result. Researchers sought to establish the local frequency of primary red blood cell alloantibodies responsible for hemolytic disease of the fetus and newborn, an established etiology of neonatal mortality, while documenting downstream clinical interventions.
To assess antibody-mediated sensitization, laboratory personnel deployed distinct elution techniques tailored to specific red cell surface antigens. The investigators selected the Lui freeze-thaw elution method specifically for detecting ABO antibodies due to the inherently labile binding characteristics of anti-A and anti-B antibodies. Conversely, the team utilized acid elution procedures to detect Rh and additional non-ABO red blood cell antibodies because of the technique’s demonstrated higher sensitivity for immunoglobulin G-mediated erythrocyte sensitization. The monitored clinical endpoints included the development of hyperbilirubinemia, admission to the neonatal intensive care unit, and the requirement for red blood cell transfusions.
Among the 267 direct antiglobulin test-positive newborns, ABO incompatibility represented the most common diagnosis, identified in 204 cases or 76 percent of the positive cohort. Within this predominant group, sensitization driven by blood type B antibodies formed the primary subset, comprising 106 cases.
Suspected Rh incompatibility constituted the second largest diagnostic grouping, encompassing 63 infants, or 23.5 percent of the positive testing cohort. Laboratory elution confirmed Rh antibody-mediated sensitization in 54 of these neonates, representing 20.2 percent of all direct antiglobulin test-positive cases. Within the confirmed Rh group, anti-D was the single most frequent causative alloantibody, documented in 28 patients. The remaining nine suspected Rh cases, representing 3.4 percent of the positive cohort, demonstrated negative eluate testing. In addition to anti-D, laboratory assays identified other clinically significant non-ABO antibodies, including anti-E in seven infants and anti-c in five infants.
Hyperbilirubinemia emerged as the primary clinical complication among sensitized infants, developing in 44 percent of the direct antiglobulin test-positive cohort. However, the study authors explicitly noted that the background incidence rate of hyperbilirubinemia across the direct antiglobulin test-negative cohort was not systematically extractable from institutional records. Because this baseline rate remains unknown, the clinical significance and exact diagnostic attribution of the 44 percent complication rate cannot be fully determined and warrants cautious clinical interpretation.
Despite the frequency of positive serologic tests and elevated bilirubin, overall clinical courses remained predominantly favorable across the sensitized group. Sixty-one percent of direct antiglobulin test-positive infants did not require admission to the neonatal intensive care unit. Furthermore, only 11 newborns, representing 4.1 percent of the positive cohort, developed hemolytic complications severe enough to necessitate red blood cell transfusions, indicating that severe hematologic compromise occurred in a small minority of identified cases.
The authors concluded that while ABO incompatibility constitutes the predominant driver of hemolytic disease of the fetus and newborn at King Fahad Medical City, the associated clinical outcomes remain largely reassuring. The investigators suggested that future evaluations might explore whether adopting a selective maternal-targeted direct antiglobulin testing strategy, integrated with comprehensive prenatal maternal antibody profiling, could optimize diagnostic healthcare resources while preserving newborn clinical safety. However, the researchers emphasized that this concept remains hypothesis-generating from single-center retrospective data, underscoring that rigorous direct comparative trials assessing universal versus selective screening and broader multi-center studies are required before clinical policy modifications are implemented.
Subject of Research: Epidemiology, alloantibody profiles, and clinical outcomes of hemolytic disease of the fetus and newborn identified through universal direct antiglobulin test screening in Saudi Arabia
Article Title: Hemolytic disease of the fetus and newborn: epidemiology, antibody profile, and clinical outcomes from universal direct antiglobulin test screening. A retrospective study from Saudi Arabia
Article References: Alfalah, Y. A., Husein, J. H., Khayata, R. M., Alkahwaji, S., Sajid, M. R., Aldosari, S., Alsughayir, A., Alkhalifah, M., Abobakr, S. B., Alhowaidi, H., & Alsaif, A. (2026). Hemolytic disease of the fetus and newborn: epidemiology, antibody profile, and clinical outcomes from universal direct antiglobulin test screening. A retrospective study from Saudi Arabia. Frontiers in Medicine, 13, Article 1921820. https://doi.org/10.3389/fmed.2026.1921820
Image Credits: AI Generated
DOI: 10.3389/fmed.2026.1921820
Keywords: Hemolytic Disease of the Fetus and Newborn, HDFN, Direct Antiglobulin Test, Universal DAT Screening, ABO Incompatibility, Rh Incompatibility, Anti-D Alloantibody, Anti-E Alloantibody, Anti-c Alloantibody, Lui Freeze-Thaw Elution, Acid Elution, Hyperbilirubinemia, Neonatal Intensive Care Unit, Red Blood Cell Transfusion, King Fahad Medical City, Saudi Arabia, Newborn Screening, Neonatal Hematology
News Source: Harold Sullivan. (November 21, 2026). ABO Incompatibility Caused Most Newborn Hemolytic Cases in Saudi Screening Study. Scienmag.



